Translating science from concept to commercial viability requires experience in drug discovery, development, and commercialization. Our board has extensive experience spanning decades in these areas.

Dr. Weber joined Domain in 2001 as a partner, where he specializes in creating companies around promising new pharmaceutical products. He has been the founding CEO of multiple biopharmaceutical companies in the Domain portfolio, including Acea Pharmaceuticals, Ascenta Therapeutics, Calixa Therapeutics, Cytovia, Domain Antibacterial Acquisition Corporation, NovaCardia, Novacea, Novalar Pharmaceuticals, Ocera Therapeutics, Orexigen Therapeutics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics, and Tragara Pharmaceuticals. He currently serves as interim CEO of Calixa Therapeutics and Sonexa Therapeutics, two seed-stage biopharmaceutical companies.

He is Chairman of the Board at Ascenta Therapeutics, Ocera Therapeutics, Orexigen Therapeutics, Sequel Pharmaceuticals, Syndax Pharmaceuticals, and Tobira Therapeutics. He was Chairman of Peninsula Pharmaceuticals until the company was sold to Johnson & Johnson in 2005, Chairman of Cerexa until the company was sold to Forest Laboratories in January 2007, Chairman of NovaCardia until the company was sold to Merck in September 2007, and a board member of Conforma Therapeutics and Cabrellis Pharmaceuticals until they were sold to Biogen-IDEC and Pharmion, respectively. In addition, he is a board member of BioVascular and DiObex.

Until 1995, Mr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. He has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. He is the inventor or co-inventor of over 40 patents and patent applications, and he has published over 130 papers in scientific journals.

Dr. Kamdar is a Principal at Domain Associates. Present board memberships include Rox Pharmaceuticals, Syndax, Tragara, and Tramoxia, as well as observer status at GenVault and Achaogen. Additionally, Dr. Kamdar serves as an advisory board member for Evolvence US-India Life Sciences.

Before joining Domain, Dr. Kamdar was a Kauffman Fellow with MPM Capital. Dr. Kamdar was formerly a Research Director at Novartis. She built and led a research team that focused on the biology, genetics, and genomics of model organisms to uncover small molecules that modulated signaling pathway networks.

Dr. Kamdar is a founder of Aryzun Pharmaceuticals, a biotech company utilizing protein-protein interaction mapping for small-molecule discovery with an initial focus on anti-infectives and oncology.

Dr. Kamdar is the author of 11 papers as well as an inventor on seven patents. Dr. Kamdar received her BA from Northwestern University and her PhD from Emory University.

Mr. Klausner joined Pappas Ventures in 2005 as a Partner. From 1990 to 2004, he was with Domain Associates, serving as a General Partner from 1997 through 2004.

Before becoming a venture capitalist, he spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology.

Mr. Klausner has previously been a board member at Santarus (IPO in 2004, NASDAQ: SNTS), X-Ceptor (acquired by Exelixis in 2004), and Altea Therapeutics, and he was a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson in 2005) and Cerexa (acquired by Forest Laboratories in 2007). He is currently a board observer at CeNeRx BioPharma.

Mr. Klausner earned a BA in Biology from Princeton University and an MBA from Stanford University.

Dr. Steven St. Peter joined MPM Capital with experience from Apax Partners and The Carlyle Group, where his investment scope included both venture and buyout transactions across medical technology and pharmaceuticals. He began working at MPM in 2003 and was promoted to General Partner in 2005. He is a director of Helicos, Omrix, PharmAthene, Xanodyne, and Syndax and previously served on the boards of Atugen and IDEA.

Dr. St. Peter is board certified in internal medicine and was previously an Assistant Clinical Professor of Medicine at Columbia University. Prior to his medical training, he was an investment banker at Merrill Lynch.

He completed his MD at Washington University and his residency and fellowship at the Hospital of the University of Pennsylvania. He also holds an MBA from the Wharton School of the University of Pennsylvania and a BA in Chemistry from the University of Kansas.

Formerly Vice President of Oncology at Rhone-Poulenc Rorer (now Sanofi-Aventis) and Chief Operating Officer of CombinatoRx, Inc., Dr. Horobin has more than 20 years of pharmaceutical drug development experience in multiple therapeutic areas, with a focus on oncology and a particular interest in the development of combination strategies.

At Rhone-Poulenc Rorer she led the global oncology business, including directing the successful global launch, and subsequent market expansion, of Taxotere® (docetaxel). As Chief Operating Officer at CombinatoRx, a company focused on combination products, she raised over $70 million in private financing, transitioned the company from a discovery-focused start-up to a clinical-stage enterprise, and positioned the company for a successful initial public offering. Dr. Horobin was also Executive Vice President at EntreMed, a company developing angiogenesis inhibitors. She spent a year as Entrepreneur in Residence with the venture capital firm MPM Capital.

Her pharmaceutical experience spans clinical development, marketing, and general management in both public and private companies.

Dr. Horobin qualified in medicine from the Victoria University of Manchester, England, and additionally gained Membership of the Royal College of General Practitioners in the United Kingdom. She holds the Diploma of Pharmaceutical Medicine from the Royal College of Physicians in the United Kingdom.